Clinical Trials Browser

Active not recruiting × Neoplasms × tepotinib × Clear all

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms